New research involving scientists from Queen Mary University of London has found evidence of protective immunity in people up to four months after mild or asymptomatic COVID-19.
The study, published today in Science Immunology, analyzed antibody and T cell responses in 136 London healthcare workers who had mild or asymptomatic COVID-19 infection dating back to March 2020.
The team, including researchers from Queen Mary, Imperial College London and University College London, found that 89 percent of healthcare workers analyzed carried neutralizing antibodies 16-18 weeks after infection.
The researchers found most also had T cells capable of recognizing multiple different parts of the virus, however the two responses did not always persist in harmony, with some individuals showing T cell immunity but no evidence of antibodies, and vice versa.
Mr Joseph Gibbons, a Postdoctoral Research Assistant at Queen Mary, said: “Our study of SARS-CoV-2 infection in healthcare workers from London hospitals reveals that four months after infection, around 90 percent of individuals have antibodies that block the virus. Even more encouragingly, in 66 percent of healthcare workers we see levels of these protective antibodies are high and that this robust antibody response is complemented by T cells which we see reacting to various parts of the virus.”
“This is good news. It means that if you have been infected there is a good chance that you will have developed antibodies and T cells that may provide some protection if you encounter the virus again.”
Mismatched immune responses
From the outset of the pandemic, scientists across the globe have been working to understand how our immune system protects us against SARS-CoV-2, and how long this protection lasts.
Much of this debate around protective immunity has focussed on the different roles of B cells, which make antibodies, and T cells, white blood cells which work in several different ways to help protect from viruses, including direct killing.
In this study, the researchers show that whilst protective antibody responses were usually complemented by a T cell response, over half of the healthcare workers had mismatched antibody and T cell responses, and did not produce a T cell response specific to proteins found on the outer layer of the SARS-CoV-2 virus.
They also found that T cell responses tended to be higher in those with the classic, defining symptoms of COVID-19, while asymptomatic infection resulted in a weaker T cell immunity than symptomatic infection, but equivalent neutralizing antibody responses.
Understanding how this careful choreography of immune responses works in people with mild or asymptomatic infection is particularly important as they represent the largest infected group.
The new study also provides reassurance for vaccination efforts, suggesting that even following mild infection, individuals carry antibody and T cell immunity to many parts of the virus, known as epitopes. Whilst new variants are appearing, the changes to the virus don’t necessarily occur within these epitopes so it is hoped the vast majority of immune recognition can likely continue unperturbed.
Dr. Corinna Pade, a Postdoctoral Research Scientist at Queen Mary, said: “Our study in asymptomatic and mild cases gives a positive insight into the durability of immunity to SARS-CoV-2 after four months of infection. A remarkable number of around 90 percent of individuals have a joint force of strong antibodies that prevent the virus from entering, coupled with T cell responses to various parts of the virus to interfere with its survival. This is an important find as mild or even no symptoms of COVID-19 are very common and representative of most infections in the community. Such abundant immune responses also give hope for the long-lasting efficacy of vaccines.”
Áine McKnight, Professor of Viral Pathology at the Blizard Institute at Queen Mary, added: “Finally, here is the evidence of lasting antibody and T-cell immunity to SARS-CoV-2 that many had been waiting for. Queen Mary played a unique role in enabling this study at a time when many laboratories were shutting down at the outset of the pandemic. Our lab remained active and made fundamental scientific observations that contributed to this paper. We continue to support the scientific effort against COVID-19 working with other London universities, NHS Health Trusts and Public Health England to help control the pandemic.”
Follow the latest news on the coronavirus (COVID-19) outbreak
Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Science Immunology 23 Dec 2020. DOI: 10.1126/sciimmunol.abf3698
Study finds evidence of lasting immunity after mild or asymptomatic COVID-19 infection (2020, December 24)
retrieved 24 December 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022